NCT00088959View on ClinicalTrials.gov

Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

January 31, 2009

Study Completion Date

November 30, 2010

Conditions
Recurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally

DRUG

celecoxib

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

27710

Duke University Medical Center, Durham

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00088959 - Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter